- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04968184
Skuteczność i bezpieczeństwo KBP-5074 w niekontrolowanym nadciśnieniu i umiarkowanej lub ciężkiej CKD (Clarion-CKD)
Randomizowane, wieloośrodkowe badanie fazy 3, prowadzone metodą podwójnie ślepej próby i kontrolowane placebo, mające na celu ocenę skuteczności i bezpieczeństwa antagonisty receptora mineralokortykoidowego KBP-5074 u pacjentów z niekontrolowanym nadciśnieniem i umiarkowaną lub ciężką (stadium 3b/4) przewlekłą chorobą nerek
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [eGFR {EPI}] ≥15 to ≤44 mL/min/1.73 m^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and <180 mm Hg and taking 2 or more antihypertensive medications.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Participants in this study will be recruited, screened, and enrolled at approximately 140 study sites globally.
The study will consist of the following periods:
- Pretreatment Phase: This will include prescreening assessment and screening period of up to 4 weeks and 2-week Open-label placebo Run-In period.
- A 24-week Double-blind Treatment Period (Randomization to Week 24) will include: An initial 12-week (Randomization to Week 12) and second 12-week (Week 12 to Week 24) treatment period and a second 12-week treatment period (Week 12 to Week 24), during both the periods study drug will be titrated.
- A 24-week Open-label Treatment Period (Week 24 to Week 48) during which eligible participants will receive Open-label KBP-5074.
- A 4-week Randomized Double-blind Withdrawal Period (Week 48 to Week 52) during which eligible participants will be randomized to continue their current KBP-5074 dose at the end of Open-label treatment or receive matching placebo for 4 weeks.
- A 4-week post-treatment Follow-Up Period (Week 52 to Week 56).
During, 24-week Double-blind Treatment Period, 24-week Open-label Treatment Period, and at 4-week Randomized Double-blind Withdrawal Period, the background antihypertensive medications change may or may not be allowed.
At Double-blind Treatment Period, eligible participants will be randomly assigned in a 1:1 ratio to KBP-5074 0.25 mg or matching placebo once daily (QD).
At the Randomized Double-blind Withdrawal Period, participants who meet the randomized withdrawal criteria will be randomly assigned in a 1:1 ratio to continue their current KBP-5074 dose at the end of the Open-label Treatment Period or matching placebo QD.
The study design included a pre-planned futility determination by an Independent Data Monitoring Committee (IDMC).
The trial was originally sponsored by KBP Biosciences PTE Ltd, but sponsorship was transferred to Novo Nordisk after the trial was terminated following the futility determination by IDMC.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Free State
-
Bloemfontein, Free State, Afryka Południowa, 9301
- Iatros International
-
-
Gauteng
-
Soweto, Gauteng, Afryka Południowa, 2193
- Charlotte Maxeke Johannesburg Hospital
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Afryka Południowa, 4001
- Office of Gulam Hoosain Vally
-
-
Western Cape
-
Cape Town, Western Cape, Afryka Południowa, 7530
- Tiervlei Trial Centre
-
Somerset West, Western Cape, Afryka Południowa, 7130
- Dr J.M. Engelbrecht Trial Site
-
-
-
-
New South Wales
-
Gosford, New South Wales, Australia, 2250
- Renal Research
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Austin Hospital
-
-
-
-
Kanton Sarajevo
-
Sarajevo, Kanton Sarajevo, Bośnia i Hercegowina, 71000
- Clinical Center University of Sarajevo
-
-
Republika Srpska
-
Banja Luka, Republika Srpska, Bośnia i Hercegowina, 78000
- Univerzitetski klinicki centar Republike Srpske - Internal Medicine, Nephrology
-
Foca, Republika Srpska, Bośnia i Hercegowina, 73300
- The University Hospital Foca
-
Gradiska, Republika Srpska, Bośnia i Hercegowina, 78400
- General Hospital Gradiska
-
Trebinje, Republika Srpska, Bośnia i Hercegowina, 89101
- General hospital Trebinje - Gastroenterology
-
-
Zeničko-dobojski Kanton
-
Tešanj, Zeničko-dobojski Kanton, Bośnia i Hercegowina, 72460
- General Hospital Tesanj
-
-
-
-
-
Gabrovo, Bułgaria, 5300
- Mhat Dr.Tota Venkova
-
Montana, Bułgaria, 3400
- Medical Center Hera EOOD
-
Plovdiv, Bułgaria, 4002
- UMHAT Kaspela
-
Rousse, Bułgaria, 7012
- Medical Center "Teodora"
-
Sofia, Bułgaria, 1510
- Medical Center Hera EOOD
-
Sofia, Bułgaria, 1113
- DCC 22 - Sofia
-
Sofia, Bułgaria, 1784
- Medical Center ''Synexus Sofia'' EOOD
-
Stara Zagora, Bułgaria, 6000
- University Hospital of Active Treatment Prof. Stoyan Kirkovich
-
Varna, Bułgaria, 9002
- MHAT"Sv.Anna-Varna"AD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bułgaria, 1233
- 5 th MHAT
-
Sofia, Sofia-Grad, Bułgaria, 1407
- Medical Center Excelsior
-
Sofia, Sofia-Grad, Bułgaria, 1431
- UMHAT St. Ekaterina
-
Sofia, Sofia-Grad, Bułgaria, 1612
- Comac Medical Ltd
-
-
-
-
-
Chongqing, Chiny, 400038
- The Southwest Hospital of AMU
-
Shanghai, Chiny, 200233
- Shanghai Sixth People's Hospital
-
Tianjin, Chiny, 300052
- Tianjin Medical University General Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chiny, 100034
- Peking University First Hospital
-
Beijing, Beijing Municipality, Chiny, 100029
- China-Japan Friendship Hospital
-
Beijing, Beijing Municipality, Chiny, 100730
- Beijing Hospital
-
Beijing, Beijing Municipality, Chiny, 100020
- Beijing Chao-Yang Hospital, Capital Medical University
-
Beijing, Beijing Municipality, Chiny, 100029
- Beijing An Zhen Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, Chiny, 350005
- The First Affiliated Hospital of Fujian Medical University
-
Xiamen, Fujian, Chiny, 361003
- The First Affiliated Hospital of Xiamen University
-
Xiamen, Fujian, Chiny, 361004
- Zhongshan Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Chiny, 510080
- Guangdong Provincial People's Hospital
-
Guangzhou, Guangdong, Chiny, 510180
- Guangzhou First People's Hospital - Nephrology
-
Guangzhou, Guangdong, Chiny, 510655
- The Third Affiliated Hospital, Sun Yat-sen University
-
-
Guangxi
-
Nanning, Guangxi, Chiny, 530021
- The People's Hospital of Guangxi Zhuang Autonomous Region- Nephrology
-
-
Guizhou
-
Guiyang, Guizhou, Chiny, 550004
- The Affliated Hospital of Guizhou Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, Chiny, 50004
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, Chiny
- The First Affiliated Hospital of Zhengzhou University (East Compus)
-
-
Hubei
-
Wuhan, Hubei, Chiny
- The Central Hospital of Wuhan
-
-
Hunan
-
Changsha, Hunan, Chiny, 410011
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, Chiny, 410013
- The Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, Chiny, 210029
- Jiangsu Province Hospital/ The First Affiliated Hospital with Nanjing Medical University
-
Wuxi, Jiangsu, Chiny, 214023
- Wuxi People's Hospital
-
-
Nei Mongol (mn)
-
Baotou, Nei Mongol (mn), Chiny, 014010
- The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
-
-
Ningxia
-
Yinchuan, Ningxia, Chiny, 750004
- General Hospital of Ningxia Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, Chiny, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Shandong
-
Jinan, Shandong, Chiny
- Shandong Provincial Hospital
-
Yantai, Shandong, Chiny, 264000
- Yantai Yuhuangding Hospital(Base Cpmpus)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chiny, 200000
- Shanghai General Hospital
-
-
Sichuan
-
Chengdu, Sichuan, Chiny, 610072
- Sichuan Academy of Medical Sciences
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chiny
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, Chiny
- Zhejiang Provincial People's Hospital
-
Hangzhou, Zhejiang, Chiny
- Zhejiang Hospital
-
Jinhua, Zhejiang, Chiny, 321000
- Jinhua Central Hospital
-
Wenzhou, Zhejiang, Chiny, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Split, Chorwacja, 21000
- University Hospital Center Split
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Chorwacja, 10000
- University Hospital Centre Zagreb
-
-
Osjecko-baranjska Županija
-
Vinkovci, Osjecko-baranjska Županija, Chorwacja, 32100
- Opca bolnica Vinkovci
-
-
-
-
-
Prague, Czechy, 140 21
- IKEM
-
Prague, Czechy, 160 00
- Alaron s.r.o.
-
-
Praha 4
-
Prague, Praha 4, Czechy, 149 00
- Nefrologie s.r.o.
-
-
Třebíč
-
Třebíč, Třebíč, Czechy, 674 01
- Nemocnice Trebic, p.o.
-
-
-
-
-
Batumi, Gruzja, 6010
- JSC "Evex Hospitals'
-
Tbilisi, Gruzja, 0102
- Aleksandre Aladashvili Clinic LLC
-
Tbilisi, Gruzja, 0144
- National Center of Urology Named after Laur Managadze
-
Tbilisi, Gruzja, 0112
- LTD Israel-Georgian Medical Research Clinic Helsicore
-
Tbilisi, Gruzja, 0114
- "Pineo Medical Ecosystem"LTD
-
Tbilisi, Gruzja, 0119
- JSC German Clinic
-
Tbilisi, Gruzja, 0159
- Bokhua Memorial Cardiovascular Centre
-
Tbilisi, Gruzja, 0159
- Emergency Cardiology Center named by acad. G. Chapidze
-
Tbilisi, Gruzja, 0159
- J.S.C."K.Eristavi National Center of Experimental and Clinical Surgery"
-
-
Adjara
-
Batumi, Adjara, Gruzja, 6000
- LTD "High technology hospital MEDCENTER"
-
-
Kvemo Kartli
-
Marneuli, Kvemo Kartli, Gruzja, 3000
- Ltd Marnecor
-
-
Shida Kartli
-
Gori, Shida Kartli, Gruzja, 1400
- Ministry of Defence of Georgia LEPL Giorgi Abramishvili Military Hospital
-
-
-
-
-
Barcelona, Hiszpania, 8023
- Hospital Quironsalud Barcelona
-
Barcelona, Hiszpania, 08025
- FUNDACION PUIGVERT - Nephrology Department
-
Barcelona, Hiszpania, 8035
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Hiszpania, 8003
- Hospital del Mar
-
Granada, Hiszpania, 18014
- Hospital Universitario Virgen de las Nieves
-
Lugo, Hiszpania, 27880
- Hospital público da Mariña
-
Lugo, Hiszpania, 27880
- Hospital Ribera Polusa
-
Madrid, Hiszpania, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Valencia, Hiszpania, 46026
- Hospital Universitario Y Politécnico La Fe
-
-
Valenciana, Comunidad
-
Valencia, Valenciana, Comunidad, Hiszpania, 46014
- Consorcio Hospital General Universitario de Valencia
-
-
-
-
-
Hong Kong, Hongkong
- Tung Wah Hospital
-
Hong Kong, Hongkong
- Queen Mary Hospital - Medicine
-
-
-
-
Central District
-
Petah Tikwa, Central District, Izrael, 49100
- Rabin Medical Center
-
-
Northern District
-
Nazareth, Northern District, Izrael, 16100
- Nazareth Hospital EMMS
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M4C 5T2
- Dr. Stephen S. Chow Medicine Professional Corporation
-
Waterloo, Ontario, Kanada, N2T 0C1
- Clinical Research Solutions Incorporated
-
-
-
-
-
Seoul, Korea Południowa, 03080
- Seoul National University Hospital - Nephrology
-
-
Daejeon Gwang'yeogsi [Taejon-Kwangyokshi]
-
Daejeon, Daejeon Gwang'yeogsi [Taejon-Kwangyokshi], Korea Południowa, 35015
- Chungnam National University Hospital - Nephrology
-
-
Gyeonggido [Kyonggi-do]
-
Goyang-si, Gyeonggido [Kyonggi-do], Korea Południowa, 10444
- National Health Insurance Service Ilsan Hospital - Nephrology
-
-
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea Południowa, 6273
- Gangnam Severance Hospital, Yonsei University Health System - Internal Medicine
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea Południowa, 6351
- Samsung Medical Center - Nephrology
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Korea Południowa, 6591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
-
-
Kaunas County
-
Kaunas, Kaunas County, Litwa, LT-49449
- Saules seimos medicinos centras
-
-
-
-
Kelantan
-
Kota Bharu, Kelantan, Malezja, 15586
- Hospital Raja Perempuan Zainab II
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malezja, 50586
- Hospital Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malezja, 59100
- University Malaya Medical Centre
-
-
Perak
-
Ipoh, Perak, Malezja, 30450
- Hospital Raja Permaisuri Bainun
-
Seri Manjung, Perak, Malezja, 32400
- Hospital Seri Manjung
-
-
-
-
-
Berlin, Niemcy, 12203
- Charité - Universitätsmedizin Berlin
-
Berlin, Niemcy, 10117
- Charité- Universitätsmedizin Berlin
-
Hanover, Niemcy, 30625
- Medizinische Hochschule Hannover
-
Jena, Niemcy, 07747
- Universitätsklinikum Jena
-
-
Baden-Wurttemberg
-
Villingen-Schwenningen, Baden-Wurttemberg, Niemcy, 78052
- Nephrologisches Zentrum Villingen-Schwenningen
-
-
North Rhine-Westphalia
-
Dortmund, North Rhine-Westphalia, Niemcy, 44137
- Diabeteszentrum DO
-
Düsseldorf, North Rhine-Westphalia, Niemcy, 23538
- DaVita Clinical Research Germany GmbH
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Niemcy, 55131
- Universitätsklinikum Mainz
-
-
-
-
-
Katowice, Polska, 40-040
- Synexus Polska Sp. z o.o.
-
Lodz, Polska, 90127
- Synexus Polska Sp. z. o.o.
-
Lodz, Polska, 92-213
- SP ZOZ Centralny Szpital Kliniczny UM w Lodzi
-
Lublin, Polska, 20954
- Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
-
Poznan, Polska, 60-702
- Synexus Polska Sp. z o.o.
-
Warsaw, Polska, 02-672
- Synexus Polska Sp. z o.o.
-
Wroclaw, Polska, 51-685
- WroMedica I. Bielicka, A. Strzalkowska s.c.
-
-
Kuyavian-Pomeranian Voivodeship
-
Grudziądz, Kuyavian-Pomeranian Voivodeship, Polska, 86-300
- NZOZ Euromedica Sp. z o.o.
-
-
Lódzkie
-
Lodz, Lódzkie, Polska, 94-074
- Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
-
-
-
-
-
Belgrade, Serbia, 11000
- Military Medical Academy
-
Belgrade, Serbia, 11000
- Zvezdara University Medical Center
-
Belgrade, Serbia
- MSB General hospital - Clinical Research Center
-
Kragujevac, Serbia, 33126-3422
- Clinical Center Kragujevac
-
-
Belgrade
-
Zemun, Belgrade, Serbia, 11080
- Clinical Hospital Centre Zemun
-
-
Nišavski Okrug
-
Niš, Nišavski Okrug, Serbia, 18000
- Clinical Centre Nis
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbia, 21000
- Clinical Center Vojvodina
-
-
-
-
Alabama
-
Foley, Alabama, Stany Zjednoczone, 36535
- G & L Research, LLC
-
Huntsville, Alabama, Stany Zjednoczone, 35805
- Apogee Clinical Research, LLC
-
-
Arizona
-
Mesa, Arizona, Stany Zjednoczone, 85210
- Aventiv Research, Inc
-
-
California
-
Beverly Hills, California, Stany Zjednoczone, 90211-2285
- National Heart Institute
-
Granada Hills, California, Stany Zjednoczone, 91344
- Amicis Research Center
-
Granada Hills, California, Stany Zjednoczone, 91324
- Amicis Research Center (Valencia)
-
Lancaster, California, Stany Zjednoczone, 93534
- Amicis Research Center
-
Northridge, California, Stany Zjednoczone, 91325
- Renal Consultants Medical Group - Granada Hills
-
South Gate, California, Stany Zjednoczone, 90280
- United Clinical Research and Innovations
-
Vacaville, California, Stany Zjednoczone, 95687-3557
- Solano Kidney Care
-
Victorville, California, Stany Zjednoczone, 92392
- Desert Cities Dialysis - Amethyst
-
Victorville, California, Stany Zjednoczone, 92395
- Kidney and Hypertension Center
-
-
Connecticut
-
Bloomfield, Connecticut, Stany Zjednoczone, 06002
- Davita Clinical Research-Hartford
-
-
Florida
-
Bradenton, Florida, Stany Zjednoczone, 34208
- Synergy Healthcare
-
Miami, Florida, Stany Zjednoczone, 33155
- Allied Biomedical Research Institute
-
Miami, Florida, Stany Zjednoczone, 33126
- LCC Medical Research
-
Miami, Florida, Stany Zjednoczone, 33032-8225
- Homestead Associates in Research, Inc
-
Miami, Florida, Stany Zjednoczone, 33126-3422
- Total Research Group
-
Miami, Florida, Stany Zjednoczone, 33144
- Oceane 7 Medical&Research Center, Inc.
-
Miami, Florida, Stany Zjednoczone, 33166
- South Florida Research Phase I-Iv, Inc.
-
Miami Lakes, Florida, Stany Zjednoczone, 33014
- Inpatient Research Clinic, LLC
-
Miami Lakes, Florida, Stany Zjednoczone, 33014-5602
- San Marcus Research Clinic, Inc.
-
Naples, Florida, Stany Zjednoczone, 34104
- New Generation Of Medical Research
-
Ocala, Florida, Stany Zjednoczone, 34471
- Sarkis Clinical
-
Orlando, Florida, Stany Zjednoczone, 32808
- Omega Research Orlando, LLC
-
Tampa, Florida, Stany Zjednoczone, 33603
- Genesis Clinical Research
-
Tampa, Florida, Stany Zjednoczone, 33604
- Santos Research Center CORP
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Fides Clinical Research
-
Augusta, Georgia, Stany Zjednoczone, 30904
- Southeastern Clinical Research Institute, LLC
-
Columbus, Georgia, Stany Zjednoczone, 31904-3650
- Columbus Associates LLC
-
Macon, Georgia, Stany Zjednoczone, 31201-6863
- Central Georgia Kidney Specialists
-
-
Illinois
-
Gurney, Illinois, Stany Zjednoczone, 60031
- Clinical Investigation Specialists, Inc.
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital (MGH) - Renal Associates Clinic
-
-
Minnesota
-
Edina, Minnesota, Stany Zjednoczone, 55435-2129
- InterMed Consultants
-
-
Missouri
-
Hazelwood, Missouri, Stany Zjednoczone, 63042
- Healthcare Research Network
-
Kansas City, Missouri, Stany Zjednoczone, 64111-5964
- Clinical Research Consultants
-
St Louis, Missouri, Stany Zjednoczone, 63136-6111
- St. Louis Heart and Vascular, P.C. (SLHV) - Christian Hospital Office
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89102-1682
- Healor Primary Care /CCT Research
-
Las Vegas, Nevada, Stany Zjednoczone, 89128
- DaVita Clinical Research (Nevada)
-
-
New York
-
Jamaica, New York, Stany Zjednoczone, 11432
- NYC Health + Hospitals / Queens - Diabetes Center of Excellence
-
Ridgewood, New York, Stany Zjednoczone, 11385
- Mattoo & Bhat Medical Associates, PC
-
The Bronx, New York, Stany Zjednoczone, 10461-1900
- Albert Einstein's College of Medicine
-
The Bronx, New York, Stany Zjednoczone, 10461-2710
- Kidney Medical Associates, PLLC
-
-
North Carolina
-
Asheville, North Carolina, Stany Zjednoczone, 28801-4104
- Mountain Kidney & Hypertension Associates (MKHA), P.A - Asheville
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- Physicians East, PA
-
Jacksonville, North Carolina, Stany Zjednoczone, 28546
- Eastern Nephrology Associates - Jacksonville
-
New Bern, North Carolina, Stany Zjednoczone, 28562-5200
- Eastern Nephrology Associates - New Bern
-
Raleigh, North Carolina, Stany Zjednoczone, 27609-7511
- North Carolina Nephrology P.A.
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27103-7108
- Brookview Hills Research Associates, LLC
-
-
Ohio
-
Dayton, Ohio, Stany Zjednoczone, 45439
- Providence Health Partners-Center for Clinical Research
-
-
South Carolina
-
Columbia, South Carolina, Stany Zjednoczone, 29203-6476
- Columbia Nephrology Associates, PA
-
-
Tennessee
-
Knoxville, Tennessee, Stany Zjednoczone, 37923-3624
- Knoxville Kidney Center, PLLC
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78503
- Gamma Clinical Research Institute
-
El Paso, Texas, Stany Zjednoczone, 79925
- Davita Clinical Research El Paso
-
El Paso, Texas, Stany Zjednoczone, 79935
- Kidney Consultants of El Paso, P.A.
-
Houston, Texas, Stany Zjednoczone, 77099
- Pioneer Research Solutions, Inc.
-
Houston, Texas, Stany Zjednoczone, 77004
- DaVita Clinical Research Houston
-
San Antonio, Texas, Stany Zjednoczone, 78251
- DaVita Clinical Research
-
San Antonio, Texas, Stany Zjednoczone, 78212-4738
- Clinical Advancement Center, PLLC
-
San Antonio, Texas, Stany Zjednoczone, 78229-3342
- Urology San Antonio - North Central
-
The Woodlands, Texas, Stany Zjednoczone, 77384
- Kidney Specialists of North Houston, PLLC
-
-
Virginia
-
Norfolk, Virginia, Stany Zjednoczone, 23502
- Davita Norfolk Square
-
Richmond, Virginia, Stany Zjednoczone, 23219
- Dominion Medical Associates, Inc.
-
-
Wisconsin
-
Kenosha, Wisconsin, Stany Zjednoczone, 53142
- Clinical Investigation Specialists
-
Wauwatosa, Wisconsin, Stany Zjednoczone, 53226
- Milwaukee Nephrologists, SC (Rich)
-
-
-
-
-
Taichung, Tajwan, 406
- China Medical University Hospital - Nephrology - Taichung
-
Taipei, Tajwan, 110
- Taipei Medical University - Shuang Ho Hospital - Nephrology
-
Taoyuan, Tajwan, 33305
- Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Nephrology
-
-
Taichung Municipality
-
Taichung, Taichung Municipality, Tajwan, 40705
- Taichung Veterans General Hospital - Nephrology
-
-
Taipei Special Muncipality
-
Taipei, Taipei Special Muncipality, Tajwan, 10002
- National Taiwan University Hospital - Nephrology
-
-
-
-
-
Budapest, Węgry, 1083
- Semmelweis Egyetem
-
Budapest, Węgry, 1204
- Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet
-
Kaposvár, Węgry, H-7400
- Somogy Megyei Kaposi Mór Oktató Kórház
-
-
Baranya
-
Pécs, Baranya, Węgry, 7624
- Coromed-Smo Kft.
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Węgry, 3530
- IPR Hungary Kft.
-
-
Csongrád megye
-
Szeged, Csongrád megye, Węgry, 6725
- Sonocor Egészségügyi Szolgáltató Kft.
-
-
Győr-Moson-Sopron
-
Mosonmagyaróvár, Győr-Moson-Sopron, Węgry, 7624
- TaNa Med Kft
-
-
Heves County
-
Hatvan, Heves County, Węgry, H-3000
- BKS Research
-
-
Pest County
-
Kistarcsa, Pest County, Węgry, 2143
- Kistarcsai Flor Ferenc Korhaz
-
-
Veszprém City
-
Balatonfüred, Veszprém City, Węgry, 8230
- DRC Gyógyszervizsgáló Központ Kft.
-
-
-
-
-
Riga, Łotwa
- P.Stradina Clinical University Hospital
-
-
Ogre
-
Ogre, Ogre, Łotwa
- Dace Teterovska - Doctor's Practice
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Body mass index (BMI) must be ≥19 to <45 kg/m^2 at the Screening Visit
-
Participant must have uncontrolled hypertension defined as meeting both of the following criteria:
- The participant has a resting seated trough cuff SBP ≥140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period
- The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3)
-
The participant must have Stage 3b (eGFR [EPI] ≥30 and ≤44 mL/min/1.73 m^2) or Stage 4 (eGFR [EPI] ≥15 and <30 mL/min/1.73 m^2) CKD.
Exclusion Criteria:
- Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period
- Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-In Periods
- Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1)
- Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3)
- Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period as assessed at the Randomization Visit (Visit 3)
- Participant has taken an mineralocorticoid receptor antagonist (MRA), a potassium-sparing diuretic, or chronic potassium supplements during the 4 weeks before the Screening Visit (Visit 1)
- Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)
- Participant has taken a strong cytochrome P450 (CYP) CYP3A4 inducer or strong CYP3A4 inhibitor during the 7 days before the Randomization Visit (Visit 3)
- Participant has taken a prohibited traditional Chinese medication during the 28 days prior to Screening Visit (Visit 1).
- Participant was administered any other investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit 1).
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Komparator placebo: Placebo
Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. |
Participants will orally receive placebo matching to KBP-5074 tablets QD. |
|
Eksperymentalny: KBP-5074
Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. |
Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12
Ramy czasowe: From baseline to Week 12
|
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated. |
From baseline to Week 12
|
|
Change in Seated Trough Cuff SBP From Week 48 to Week 52
Ramy czasowe: From Week 48 to Week 52
|
Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated. |
From Week 48 to Week 52
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Change in Seated Trough Cuff SBP From Baseline to Week 24
Ramy czasowe: From baseline to Week 24
|
Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated. |
From baseline to Week 24
|
|
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12
Ramy czasowe: From baseline to Week 12
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated. |
From baseline to Week 12
|
|
Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline
Ramy czasowe: From baseline to Week 12
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. |
From baseline to Week 12
|
|
Percentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline
Ramy czasowe: From baseline to Week 12 and Week 24
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From baseline to Week 12 and Week 24
|
|
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24
Ramy czasowe: From baseline to Week 24
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated. |
From baseline to Week 24
|
|
Changes in Seated Trough Cuff DBP From Baseline to Week 48
Ramy czasowe: From baseline to Week 48
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated. |
From baseline to Week 48
|
|
Changes in Seated Trough Cuff SBP From Baseline to Week 48
Ramy czasowe: From baseline to Week 48
|
Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated. |
From baseline to Week 48
|
|
Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline
Ramy czasowe: From baseline to Week 24
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated. |
From baseline to Week 24
|
|
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Ramy czasowe: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Ramy czasowe: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Change in Seated Trough Cuff DBP From Week 48 to Week 52
Ramy czasowe: From Week 48 to Week 52
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated. |
From Week 48 to Week 52
|
|
Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline
Ramy czasowe: Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline
Ramy czasowe: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Ramy czasowe: Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
|
The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease. |
Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
|
|
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Ramy czasowe: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Ramy czasowe: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Ramy czasowe: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Ramy czasowe: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Ramy czasowe: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Ramy czasowe: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby naczyniowe
- Choroby układu krążenia
- Procesy patologiczne
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby nerek
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Przewlekła choroba
- Atrybuty choroby
- Niewydolność nerek
- Stany patologiczne, oznaki i objawy
- Nadciśnienie
- Niewydolność nerek, przewlekła
- KBP-5074
Inne numery identyfikacyjne badania
- KBP5074-3-001
- 2021-003636-88 (Numer EudraCT)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .